Results from CIRSE Multicenter Registry Reinforce Safety of St. Jude Medical Vascular Closure Device

ST. PAUL, Minn., Dec 09, 2010 (BUSINESS WIRE) --

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, commends the efforts of the investigators in the CIRSE Vascular Closure Device Registry, the world's first multicenter registry aimed at assessing the performance of vascular closure devices in interventional radiology (IR) procedures.

With more than 1,100 patients enrolled at 28 centers in 10 European countries, the CIRSE registry validated the routine use of Angio-Seal(TM) vascular closure devices in IR, with successful deployment achieved in approximately 97 percent of procedures. The registry was conducted under the leadership of Principal Investigator Jim A. Reekers, M.D., Ph.D., professor of interventional radiology at the University of Amsterdam, The Netherlands, and confirmed that the use of Angio-Seal vascular closure devices in IR procedures is safe and effective with low incidence of serious complications.

"The CIRSE Vascular Closure Device Registry results provide physicians with an unbiased source of information that verifies the benefits of closure devices in interventional radiology procedures," said Dr. Reekers. "The results offer strong clinical data that demonstrate the use of Angio-Seal vascular closure devices are safe and effective with outstanding deployment success rates."

source: ST. Jude Medical